3-Fluoromethamphetamine (3-FMA) is a fluorinated analog of methamphetamine in which a fluorine atom occupies the 3-position (meta) of the phenyl ring. It belongs to both the Stimulants and Entactogen psychoactive classes, reflecting a dual pharmacological profile that combines the catecholaminergic activity characteristic of methamphetamine with a serotonergic component that produces mild empathogenic and mood-enhancing effects.
3-FMA's effect profile positions it between 2-FMA (a relatively pure dopaminergic/noradrenergic stimulant) and 4-FA (which produces stronger MDMA-like entactogenic effects). At moderate doses, community reports describe a combination of sustained focus, energy, and social enhancement — a stimulant foundation overlaid with emotional warmth and openness that falls short of the full entactogenic immersion of 4-FA but exceeds the social coldness of 2-FMA. This hybrid profile makes it appealing for both work-related use and social recreation.
Despite its dual-class designation, 3-FMA carries all the risks associated with releasing agents acting on serotonin: potential neurotoxicity with heavy use, more pronounced comedowns than purely dopaminergic stimulants, and heightened risk of serotonin syndrome in drug combinations. Formal human pharmacological and toxicological data do not exist, and all risk characterization relies on structural analogy and community experience.
Safety at a Glance
High Risk- Treat as a Partial Entactogen
- Critical Drug Interactions
- Toxicity: Overview The toxicity of 3-FMA has not been formally studied. As a presumed triple releasing agent with serotonergic ...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid (+3 more)
- Overdose risk: Stimulant overdose from 3-FMA is a medical emergency primarily involving cardiovascular and neuro...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 3 hrs – 7 hrsHow It Feels
The onset of 3-FMA arrives within thirty to fifty minutes as a balanced upwelling of energy and warmth. There is a building alertness in the mind and a subtle expansion of emotional openness, the two qualities rising together in a blend that gives the substance its distinctive character. Heart rate increases gently, a mild warmth spreads through the chest, and there is a growing sense that both tasks and people are more interesting than they were an hour ago.
As the effects develop over the next hour, 3-FMA reveals itself as a genuine hybrid. The stimulant dimension provides clean, sustained focus and physical energy. The empathogenic dimension softens the clinical edge that pure stimulants can carry, adding a warmth to social interactions and a richness to sensory experience that would be absent from a purely dopaminergic compound. Music sounds notably better. Conversations feel engaging and meaningful. There is enough cognitive enhancement to be productive and enough emotional warmth to be genuinely sociable, a combination that many find uniquely versatile.
At the peak, typically two to three hours in, the balance holds steady. The stimulation is firm but never jittery. The empathogenic warmth is present but never overwhelming. The jaw clenches with moderate persistence, appetite is suppressed, and the body runs slightly warm. Mood is elevated into a zone of confident, sociable optimism. Physical movement feels good, and there is enough energy for sustained activity, whether that means dancing, working, or extended conversation. The headspace remains clear and functional throughout, with none of the confusion or cognitive impairment that can accompany more serotonergically heavy compounds.
The duration of 3-FMA is notable, typically six to eight hours of primary effects with a gradual taper rather than a sudden drop. As the experience winds down, the empathogenic component fades first, leaving behind a residual stimulation that eventually gives way to mild fatigue. The comedown is generally smooth, less punishing than strongly serotonergic substances and less abrupt than shorter-acting stimulants. Sleep may be delayed but arrives without major difficulty. The following day is typically unremarkable, with at most a slight tiredness that resolves by afternoon.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(2)
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(6)
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
3-FMA is believed to act as a triple releasing agent — releasing dopamine, norepinephrine, and serotonin by reversing their respective transporters (DAT, NET, SERT). This is analogous to MDMA's mechanism, but with different relative release ratios: 3-FMA is expected to favor catecholamine (DA/NE) release over serotonin release more than MDMA does, producing less intense entactogenic effects and more pronounced stimulation.
The meta fluorine substitution on the phenyl ring modulates the compound's binding kinetics and release potency relative to unsubstituted methamphetamine. The specific quantitative ratios of DA:NE:5-HT release for 3-FMA have not been formally characterized.
Receptor Profile
- DAT — Significant releasing agent activity; drives stimulation and focus
- NET — Norepinephrine release contributes to wakefulness and cardiovascular effects
- SERT — Moderate serotonin releasing activity; produces the empathogenic, sociability-enhancing component
Pharmacokinetics
No formal data available. Community-reported estimates:
- Onset: 30–60 minutes orally
- Peak: 2–3 hours
- Duration: 6–10 hours
- Longer duration than methamphetamine's closest recreational analog profile, likely due to fluorine-mediated metabolic resistance
Comparison with Related Compounds
3-FMA occupies an intermediate position between 2-FMA (more purely stimulant) and 3-FEA/4-FA (more entactogenic). Its methyl group on the nitrogen (compared to 3-FA) increases CNS penetration and overall potency, similar to the methamphetamine vs. amphetamine distinction.
Detection Methods
Standard Drug Panel Inclusion
3-FMA (3-Fluoromethamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.
Urine Detection
Due to the structural similarity to amphetamine, 3-FMA (3-Fluoromethamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 3-FMA (3-Fluoromethamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 3-FMA (3-Fluoromethamphetamine) unless the specific assay has unusually broad cross-reactivity.
Blood and Saliva Detection
3-FMA (3-Fluoromethamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.
Hair Follicle Detection
Hair follicle analysis can theoretically detect 3-FMA (3-Fluoromethamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 3-FMA (3-Fluoromethamphetamine).
Confirmatory Testing
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 3-FMA (3-Fluoromethamphetamine). These techniques can distinguish 3-FMA (3-Fluoromethamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 3-FMA (3-Fluoromethamphetamine) must be available to the testing laboratory for positive identification.
Reagent Testing
Marquis reagent produces no reaction or a faint orange-brown color with 3-FMA (3-Fluoromethamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 3-FMA (3-Fluoromethamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MAOI | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Myristicin | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,4-Butanediol | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1B-LSD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1cP-AL-LAD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1cP-LSD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
History
Development Context
3-FMA emerged as part of the fluorinated methamphetamine analog series — parallel to the fluoroamphetamine series — in the research chemical market of the early-to-mid 2010s. Its synthesis was a logical extension of structure-activity work in the fluorinated amphetamine space, introducing an N-methyl group (converting amphetamine to methamphetamine framework) to increase CNS penetrance and potency.
Position in the Market
3-FMA occupies a specific niche between the functional productivity stimulants (2-FMA) and the more overtly MDMA-adjacent compounds (4-FA, MDMA analogs). Its dual stimulant-entactogen profile has attracted interest from users seeking a "social stimulant" effect — something with more emotional character than 2-FMA but more manageable and durable than 4-FA. It has remained a relatively niche compound with a dedicated but not large user base in research chemical communities.
Regulatory Status
Like other fluorinated amphetamine analogs, 3-FMA is unscheduled in many jurisdictions but falls under amphetamine analog provisions in others. Sweden, the UK, and several EU member states have brought various fluoroamphetamines under controlled substance legislation.
Harm Reduction
Treat as a Partial Entactogen
Because 3-FMA has meaningful serotonergic activity, it should be treated with the same caution as entactogens like 4-FA or MDA regarding use frequency, not just as a "stimulant with mild social effects." The 3-month rule (used for MDMA) need not be applied identically, but use should be infrequent — no more than once monthly — to allow neurobiological recovery of serotonergic systems.
Critical Drug Interactions
- MAOIs — Absolute contraindication; risk of fatal serotonin syndrome
- SSRIs/SNRIs — Risk of serotonin syndrome; both pharmacodynamic interaction and receptor competition
- Other entactogens — Combining with MDMA, 4-FA, or MDA multiplies serotonergic load unsafely
- Lithium — Avoid in combination with any releasing agent
Dose and Duration Guidance
- Common oral dose: Estimated 20–40 mg
- Duration: Plan for 6–10 hours; do not dose after early afternoon
- Avoid redosing; the stimulant profile can make it tempting to top up, but added serotonergic burden increases risk
Allow Recovery Time
Post-use low mood is common with triple releasing agents. Plan for low-intensity days following use. Avoid stacking use days back-to-back.
Toxicity & Safety
Overview
The toxicity of 3-FMA has not been formally studied. As a presumed triple releasing agent with serotonergic activity, it carries a risk profile that includes both the cardiovascular risks of stimulants and the potential neurotoxic and serotonin syndrome risks of serotonergic agents.
Serotonergic Neurotoxicity
The key toxicological concern distinguishing 3-FMA from purely dopaminergic stimulants is its potential serotonergic neurotoxicity. Compounds that cause sustained, high-magnitude serotonin release — such as MDMA — are associated with neurotoxic damage to serotonergic axon terminals at high doses or with frequent heavy use. The degree to which 3-FMA shares this risk is unknown, but the risk cannot be dismissed.
Serotonin Syndrome Risk
The serotonin releasing activity of 3-FMA creates meaningful risk of serotonin syndrome when combined with other serotonergic substances — SSRIs, SNRIs, MAOIs, other serotonergic entactogens, tramadol, or lithium. This represents an important drug interaction hazard.
Cardiovascular Risk
Standard sympathomimetic cardiovascular risks apply: elevated heart rate, blood pressure, risk of arrhythmia with heavy use.
Comedown Profile
The serotonergic component produces more significant comedowns than purely dopaminergic stimulants. Community experience reports include the familiar post-entactogen "comedown" of low mood, fatigue, and difficulty feeling pleasure for 1–3 days following use — analogous to a mild version of the MDMA comedown.
Overdose Information
Stimulant overdose from 3-FMA is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | Develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
3-FMA is currently a grey area compound within many parts of the world. People may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Canada: 3-FMA would be considered Schedule I as it is an analogue of Amphetamine.
China: As of October 2015 3-FMA is a controlled substance in China.
France: As of december 2024, 3-FMA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 3-FMA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
New Zealand: 3-FMA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
Switzerland: 3-FMA is a controlled substance specifically named under Verzeichnis E.
The Netherlands:** 3-FMA is a controlled substance as of July 1, 2025.
Turkey:** 3-FMA is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 3-FMA is considered a Class A drug as a result of the amphetamine analog clause of the Misuse of Drugs Act 1971.
United States: 3-FMA may be considered an analogue of amphetamine under the Federal Analogue Act. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Designer drug
Stimulants
Substituted amphetamines
3-FMA (Wikipedia)
3-FMA (Isomer Design)
Experience Reports (1)
Tips (3)
Have a landing plan for the 3-FMA comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
Start low with 3-FMA and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
If you snort 3-FMA, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- 3-FMA - TripSit Factsheet
TripSit factsheet for 3-FMA
tripsit - 3-FMA - Wikipedia
Wikipedia article on 3-FMA
wikipedia